Drug intelligence / Profile preview

GC2129A

Development stage: Phase 1
Lead developer: GC Biopharma
Modality: Small Molecules
Administration: Oral

Overview

GC2129A is an investigational oral small molecule drug developed by GC Biopharma Corp. It is currently being evaluated in a Phase 1 clinical trial to assess its safety and pharmacokinetics in healthy adult volunteers under fasting conditions. The study uses a randomized, open-label, crossover design with reference drugs for comparison. The primary indication under investigation is type 2 diabetes; however, the specific mechanism of action and molecular target have not been disclosed in publicly available sources[1][7]. The developer and sponsor of the clinical trial is GC Biopharma Corp.

Beyond the preview

Go deeper on GC2129A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC2129A.

Explore the full profile